

Daejeon Regional Office of Food and Drug Safety

166 Cheongsu-ro, Seo-gu, Daejeon, 302828, Korea

Tel : +82-42-480-8710, Fax : +82-42-480-8715

Certificate of a Pharmaceutical Product

- ┌ No. of Certificate : 2016-G1-0329
- ├ Exporting (certifying) country : Republic of Korea
- └ Importing (requesting) country : Bangladesh

1. Applicant (=Product-license holder)

(This certificate shall not be issued to others than the product-license holder)

- Name : Dongkook Pharmaceutical Co., Ltd.
- Address : 33-19, Yongso 2-gil, Gwanhyewon-myeon, Jincheon-gun, Chungcheongbuk-do, Republic of Korea

2. Name and dosage form of product

: Hyaron Prefilled Injection / Solution for injection in prefilled syringe

Product Name in Korean : 히야론프리필드주사(히알루론산나트륨)

2.1. Number of product license and date of issue

: No. 1416-143 / Oct. 27, 1993

2.2. Active ingredient(s) and amount(s) per unit dose

(For Complete quantitative composition including excipients, see attached.)

: Each mL contains

Active ingredient : Sodium Hyaluronate ----- 10 mg

2.3. Is this product licensed to be placed on the market for use in the exporting country ?

┌ Yes (O) ⇒ fill out section A, omit section B.

└ No () ⇒ omit section A, fill out section B.

A.1. Is this product actually on the market in the exporting country ?

Yes(O) / No() / Unknown()

A.2. Is Summary Technical Basis of Approval appended ?

Yes() / No(O)

A.3. Is the attached, officially approved product information complete and consonant with the license ? : Yes() / No() / Not provided(O)

B.1. Why is marketing authorization lacking?

┌ not required (just Applicant's option, even possible) ()

└ not requested (not reviewed for marketing) ()

└ under consideration ()

└ refused ()

B.2. Remarks (the reason not requesting registration) :

2.4. Status of product-license holder

a (O) manufactures the dosage form

b () consigns partially the manufacturing process to other company

- In case of "b", the manufacturer's

· Name :

· Address :

· Consigned process :

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? : YES

※ Inspection of each dosage form is implemented by the administrative authority under the provision of the Pharmaceutical Affairs Act.


3.1. Periodicity of routine inspection(years) : 3 years

3.2. Has the manufacture of this type of dosage form been inspected? : YES

3.3. Do the facilities and operations conform to the WHO-GMP? : YES

※ Attached, if necessary : approved product information (O)

.....



Issued date : Feb. 05, 2016

by

Director
of General Services Division
Daejeon Regional Commissioner
Food & Drug Administration

<Attachment>

Formulation

Each mL contains

Active Ingredient :

Sodium Hyaluronate (EP) ----- 10 mg

Inactive Ingredients :

Sodium chloride (KP) ----- 8.5 mg

Dibasic Sodium Phosphate Hydrate (KP) ----- q.s.

Monobasic Sodium Phosphate (USP) ----- q.s.

Water for Injection (KP) ----- q.s.

